Great find Simon. I hope that Ms. Woodcock is speaking to others in the FDA about this. Ira Shoulson presented data at the AGM which shows repeated, closely mirrored, improvement in executive function results between the 2A and REACH2HD. That along with public comments from patients relating to the FDA Patient-focused HD meeting should be supportive and strong evidence for PBT2 helping HD patients, in my opinion.
FDA Official statement Urges Drug Developers to Focus on Data, page-4
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $18.62M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 47 | 56016034 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 128956244 | 21 |
View Market Depth
| Last trade - 10.10am 04/09/2024 (20 minute delay) ? |
| ATH (ASX) Chart |
Day chart unavailable